Emergent BioSolutions Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported negative sales was USD 4.5 million compared to sales of USD 87.3 million a year ago. Revenue was USD 242.7 million compared to USD 397.5 million a year ago. Net loss was USD 56.4 million compared to net income of USD 4.6 million a year ago. Basic loss per share from continuing operations was USD 1.13 compared to basic earnings per share from continuing operations of USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 1.13 compared to diluted earnings per share from continuing operations of USD 0.09 a year ago.
For the six months, sales was USD 4.5 million compared to USD 203.5 million a year ago. Revenue was USD 550.2 million compared to USD 740.5 million a year ago. Net loss was USD 60.1 million compared to net income of USD 74.3 million a year ago. Basic loss per share from continuing operations was USD 1.19 compared to basic earnings per share from continuing operations of USD 1.4 a year ago. Diluted loss per share from continuing operations was USD 1.19 compared to diluted earnings per share from continuing operations of USD 1.37 a year ago.